These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32972198)

  • 21. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings.
    Poletti P; Merler S; Ajelli M; Manfredi P; Munywoki PK; Nokes D; Melegaro A
    BMC Med; 2015 Mar; 13():49. PubMed ID: 25857701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy.
    Scheltema NM; Kavelaars XM; Thorburn K; Hennus MP; van Woensel JB; van der Ent CK; Borghans JAM; Bont LJ; Drylewicz J
    Vaccine; 2018 Jul; 36(31):4693-4700. PubMed ID: 29941327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging small and large molecule therapeutics for respiratory syncytial virus.
    Bergeron HC; Tripp RA
    Expert Opin Investig Drugs; 2020 Mar; 29(3):285-294. PubMed ID: 32096420
    [No Abstract]   [Full Text] [Related]  

  • 25. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.
    Browne SK; Beeler JA; Roberts JN
    Vaccine; 2020 Jan; 38(2):101-106. PubMed ID: 31706809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective.
    Wittenauer R; Pecenka C; Baral R
    BMC Med; 2023 Mar; 21(1):121. PubMed ID: 37004038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.
    Zhu T; Zhang C; Yu L; Chen J; Qiu H; Lyu W; Huang S
    Virol Sin; 2015 Oct; 30(5):371-8. PubMed ID: 26511990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiratory syncytial virus infections in India: Epidemiology and need for vaccine.
    Broor S; Parveen S; Maheshwari M
    Indian J Med Microbiol; 2018; 36(4):458-464. PubMed ID: 30880691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RSV Lower Respiratory Tract Illness in Infants of Low- and Middle-income Countries.
    Laudanno SL; Sánchez Yanotti CI; Polack FP
    Acta Med Acad; 2020 Aug; 49(2):191-197. PubMed ID: 33189124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol.
    Löwensteyn YN; Mazur NI; Nair H; Willemsen JE; van Thiel G; Bont L;
    BMC Infect Dis; 2021 Aug; 21(1):857. PubMed ID: 34425773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
    Huang K; Wu H
    Microbiol Spectr; 2014 Aug; 2(4):AID-0014-2014. PubMed ID: 26104207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
    Fuentes S; Arenas D; Moore MM; Golding H; Khurana S
    Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RSV associated hospitalizations in children in Karachi, Pakistan: Implications for vaccine prevention strategies.
    Ali A; Yousafzai MT; Waris R; Jafri F; Aziz F; Abbasi IN; Zaidi A
    J Med Virol; 2017 Jul; 89(7):1151-1157. PubMed ID: 28092107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory Syncytial Virus-Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely Collected Datasets.
    Reeves RM; van Wijhe M; Tong S; Lehtonen T; Stona L; Teirlinck AC; Fernandez LV; Li Y; Giaquinto C; Fischer TK; Demont C; Heikkinen T; Speltra I; van Boven M; Bøås H; Campbell H;
    J Infect Dis; 2020 Oct; 222(Suppl 7):S599-S605. PubMed ID: 32815542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
    Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
    Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Respiratory syncytial virus: how, why and what to do.
    Rodriguez R; Ramilo O
    J Infect; 2014 Jan; 68 Suppl 1():S115-8. PubMed ID: 24171820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model.
    Baral R; Higgins D; Regan K; Pecenka C
    BMJ Open; 2021 Apr; 11(4):e046563. PubMed ID: 33895717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.